News from vanda pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 17, 2014, 19:00 ET

Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Jun 03, 2014, 07:00 ET

European Medicines Agency Accepts HETLIOZ™ (tasimelteon) Marketing Authorization Application for Non-24-Hour Sleep-Wake Disorder in the Totally Blind

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that its Marketing Authorization Application (MAA) for oral...

Jun 02, 2014, 19:00 ET

HETLIOZ™ (tasimelteon) Data in Patients with Non-24-Hour Sleep-Wake Disorder to be presented at SLEEP 2014 meeting

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) will present additional data from its HETLIOZ™ (tasimelteon) clinical development...

May 29, 2014, 21:00 ET

Vanda Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the...

May 08, 2014, 07:00 ET

Vanda Pharmaceuticals Reports First Quarter 2014 Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the...

Apr 24, 2014, 17:30 ET

Vanda Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 8, 2014

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Apr 09, 2014, 19:00 ET

Vanda Pharmaceuticals Announces Availability of HETLIOZ™ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder (Non-24)

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the availability of HETLIOZ™.  HETLIOZ™ is the first...

Feb 28, 2014, 07:00 ET

Blind Adventurer, Erik Weihenmayer, Launches National Campaign to Raise Awareness of Non-24-Hour Sleep-Wake Disorder

 Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that it has partnered with Erik Weihenmayer, a world-renowned adventurer and...

Feb 13, 2014, 07:00 ET

Vanda Pharmaceuticals Reports Fourth Quarter 2013 and Full Year 2013 Results

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Jan 31, 2014, 13:45 ET

FDA Approves HETLIOZ™ (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder

 Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved...

Jan 23, 2014, 17:00 ET

Vanda Pharmaceuticals to Announce Fourth Quarter 2013 Financial Results on February 13, 2014

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Dec 03, 2013, 17:00 ET

Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Nov 14, 2013, 22:55 ET

FDA Advisory Committee Recommends Approval of HETLIOZ™ for the Treatment of Non-24-Hour-Disorder (Non-24) in the Totally Blind

 Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central...

Nov 14, 2013, 07:05 ET

Vanda Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review HETLIOZ™ NDA

 Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Nov 07, 2013, 06:55 ET

Vanda Pharmaceuticals Reports Third Quarter 2013 Results

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Oct 21, 2013, 19:00 ET

Vanda Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 7, 2013

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Oct 16, 2013, 16:01 ET

Vanda Pharmaceuticals Announces FDA Advisory Committee Meeting On November 14, 2013

Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has notified the company of the...

Sep 10, 2013, 17:00 ET

Vanda Pharmaceuticals to Present at the Stifel Nicolaus 2013 Healthcare Conference

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Aug 07, 2013, 08:47 ET

Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the sale of 4,680,000 shares of its common stock in an underwritten public...

Aug 06, 2013, 16:01 ET

Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it intends to offer and sell shares of its common stock in an...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge